Does the media refer more to RVTY or ADPT?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 11 mentions for Revvity. Revvity's average media sentiment score of 0.42 beat Adaptive Biotechnologies' score of 0.24 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MEDP or ADPT?

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Medpace. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 7 mentions for Medpace. Medpace's average media sentiment score of 0.42 beat Adaptive Biotechnologies' score of 0.24 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ICLR or ADPT?

In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Icon. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 2 mentions for Icon. Icon's average media sentiment score of 0.67 beat Adaptive Biotechnologies' score of 0.24 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TXG or ADPT?

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than 10x Genomics. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.53 beat Adaptive Biotechnologies' score of 0.24 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Adaptive Biotechnologies 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Adaptive Biotechnologies (ADPT) Competitors

$26.49 +0.40 (+1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$26.13 -0.36 (-1.34%)

As of 07:30 PM Eastern

Compare

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

Should you buy Adaptive Biotechnologies stock or one of its competitors? Adaptive Biotechnologies's main competitors and comparable companies include Revvity (RVTY), Medpace (MEDP), Charles River Laboratories International (CRL), Icon (ICLR), and 10x Genomics (TXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Adaptive Biotechnologies compare to Revvity?

Revvity (NYSE:RVTY) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

86.7% of Revvity shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 11 mentions for Revvity. Revvity's average media sentiment score of 0.42 beat Adaptive Biotechnologies' score of 0.24 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revvity has a net margin of 8.16% compared to Adaptive Biotechnologies' net margin of -20.73%. Revvity's return on equity of 8.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Revvity has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Revvity has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	5.95	$241.20M	$2.10	72.52
Adaptive Biotechnologies	$308.08M	13.52	-$59.50M	-$0.41	N/A

Revvity presently has a consensus target price of $120.50, indicating a potential downside of 20.87%. Adaptive Biotechnologies has a consensus target price of $28.94, indicating a potential upside of 10.91%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Revvity and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Medpace?

Medpace (NASDAQ:MEDP) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Medpace has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.78B	6.05	$451.12M	$17.06	35.33
Adaptive Biotechnologies	$308.08M	13.52	-$59.50M	-$0.41	N/A

Medpace has a net margin of 17.67% compared to Adaptive Biotechnologies' net margin of -20.73%. Medpace's return on equity of 110.15% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

78.0% of Medpace shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Medpace presently has a consensus target price of $607.73, suggesting a potential upside of 0.83%. Adaptive Biotechnologies has a consensus target price of $28.94, suggesting a potential upside of 10.91%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Medpace has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Medpace. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 7 mentions for Medpace. Medpace's average media sentiment score of 0.42 beat Adaptive Biotechnologies' score of 0.24 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medpace beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Adaptive Biotechnologies (NASDAQ:ADPT) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Adaptive Biotechnologies has higher earnings, but lower revenue than Charles River Laboratories International. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.52	-$59.50M	-$0.41	N/A
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A

Adaptive Biotechnologies has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Charles River Laboratories International had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 23 mentions for Charles River Laboratories International and 16 mentions for Adaptive Biotechnologies. Charles River Laboratories International's average media sentiment score of 0.73 beat Adaptive Biotechnologies' score of 0.24 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International has a net margin of -5.96% compared to Adaptive Biotechnologies' net margin of -20.73%. Charles River Laboratories International's return on equity of 15.75% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Adaptive Biotechnologies presently has a consensus target price of $28.94, indicating a potential upside of 10.91%. Charles River Laboratories International has a consensus target price of $300.11, indicating a potential upside of 0.83%. Given Adaptive Biotechnologies' higher probable upside, research analysts clearly believe Adaptive Biotechnologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Charles River Laboratories International beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Icon?

Icon (NASDAQ:ICLR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Icon presently has a consensus price target of $172.40, indicating a potential upside of 4.80%. Adaptive Biotechnologies has a consensus price target of $28.94, indicating a potential upside of 10.91%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.39
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Icon has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Icon. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 2 mentions for Icon. Icon's average media sentiment score of 0.67 beat Adaptive Biotechnologies' score of 0.24 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Icon has a net margin of 3.99% compared to Adaptive Biotechnologies' net margin of -20.73%. Icon's return on equity of 8.02% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

95.6% of Icon shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 44.0% of Icon shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Icon has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.53	$229.34M	$4.26	38.62
Adaptive Biotechnologies	$308.08M	13.52	-$59.50M	-$0.41	N/A

Summary

Icon beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

10x Genomics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

10x Genomics presently has a consensus target price of $58.60, indicating a potential downside of 24.17%. Adaptive Biotechnologies has a consensus target price of $28.94, indicating a potential upside of 10.91%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than 10x Genomics. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.53 beat Adaptive Biotechnologies' score of 0.24 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Adaptive Biotechnologies	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has higher revenue and earnings than Adaptive Biotechnologies. 10x Genomics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	15.66	-$43.54M	-$0.59	N/A
Adaptive Biotechnologies	$308.08M	13.52	-$59.50M	-$0.41	N/A

10x Genomics has a net margin of -12.18% compared to Adaptive Biotechnologies' net margin of -20.73%. 10x Genomics' return on equity of -9.33% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Summary

10x Genomics beats Adaptive Biotechnologies on 8 of the 15 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.23B	$10.57B	$7.20B	$13.28B
Dividend Yield	N/A	1.44%	2.53%	16.36%
P/E Ratio	-64.61	32.42	274.76	26.18
Price / Sales	13.72	503.96	628.42	97.18
Price / Cash	N/A	27.20	76.82	53.72
Price / Book	18.02	6.49	11.21	6.34
Net Income	-$59.50M	$56.67B	$3.50B	$381.90M
7 Day Performance	-6.56%	-1.09%	-0.84%	-1.39%
1 Month Performance	8.48%	8.84%	-5.42%	-4.31%
1 Year Performance	69.27%	28.78%	4.38%	-0.35%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	2.4827 of 5 stars	$26.49 +1.5%	$28.94 +9.2%	+67.8%	$4.23B	$308.08M	N/A	624	Insider Trade
RVTY Revvity	3.1006 of 5 stars	$157.14 +3.7%	$116.57 -25.8%	+65.7%	$16.91B	$2.86B	74.83	11,000	Analyst Forecast
MEDP Medpace	2.3873 of 5 stars	$620.51 +3.5%	$602.27 -2.9%	+13.5%	$16.73B	$2.78B	36.37	6,200	Analyst Forecast
CRL Charles River Laboratories International	2.6132 of 5 stars	$310.84 +7.1%	$300.11 -3.5%	+71.5%	$14.84B	$4.00B	N/A	19,700	Insider Trade Analyst Revision
ICLR Icon	3.1759 of 5 stars	$168.33 +3.9%	$172.40 +2.4%	-11.8%	$12.89B	$8.29B	39.51	40,100	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

How does Adaptive Biotechnologies compare to Revvity?

Summary

How does Adaptive Biotechnologies compare to Medpace?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Summary

How does Adaptive Biotechnologies compare to Icon?

Summary

How does Adaptive Biotechnologies compare to 10x Genomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

How does Adaptive Biotechnologies compare to Revvity?

Do insiders and institutionals believe in RVTY or ADPT?

Does the media refer more to RVTY or ADPT?

Is RVTY or ADPT more profitable?

Which has more risk & volatility, RVTY or ADPT?

Which has stronger earnings & valuation, RVTY or ADPT?

Do analysts prefer RVTY or ADPT?

Summary

How does Adaptive Biotechnologies compare to Medpace?

Which has stronger valuation & earnings, MEDP or ADPT?

Is MEDP or ADPT more profitable?

Do institutionals and insiders hold more shares of MEDP or ADPT?

Do analysts rate MEDP or ADPT?

Which has more risk & volatility, MEDP or ADPT?

Does the media refer more to MEDP or ADPT?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Which has preferable valuation and earnings, ADPT or CRL?

Which has more risk & volatility, ADPT or CRL?

Do institutionals & insiders have more ownership in ADPT or CRL?

Does the media prefer ADPT or CRL?

Is ADPT or CRL more profitable?

Do analysts prefer ADPT or CRL?

Summary

How does Adaptive Biotechnologies compare to Icon?

Do analysts recommend ICLR or ADPT?

Which has more risk & volatility, ICLR or ADPT?

Does the media refer more to ICLR or ADPT?

Is ICLR or ADPT more profitable?

Do institutionals and insiders believe in ICLR or ADPT?

Which has preferable earnings and valuation, ICLR or ADPT?

Summary

How does Adaptive Biotechnologies compare to 10x Genomics?

Which has more risk and volatility, TXG or ADPT?

Do analysts recommend TXG or ADPT?

Do institutionals & insiders believe in TXG or ADPT?

Does the media favor TXG or ADPT?

Which has preferable earnings and valuation, TXG or ADPT?

Is TXG or ADPT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools